The Center for Biosimilars® recaps the top 5 biosimilars articles for the week of April 9, 2018.
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of April 9.
Number 5: Mylan has announced that it will partner with Fujifilm Kyowa Kirin Biologics to commercialize an adalimumab biosimilar in Europe.
Number 4: A new database reveals that donations to patient advocacy groups overshadowed the total amount that pharmaceutical companies spent on federal lobbying in 2015.
Number 3: A paper newly published in The American Journal of Managed Care®, a sister publication of The Center for Biosimilars®, argues that limited distribution networks can have an anticompetitive impact on the biosimilars marketplace.
Number 2: In a press briefing at Pfizer’s headquarters, the company’s executives reviewed their progress with biosimilars to date and underscored the need for a level playing field if biosimilars are to compete with brand-name biologics in the United States.
Number 1: Sanofi has launched its follow-on insulin lispro, with list prices for its product set at an approximate 15% discount to those of the originator drug.
Finally, last week, our e-newsletter asked whether you think the US government should intervene to bring down the high cost of drugs.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.